Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 35 - Antineoplastic agents
Patents for A61P 35 - Antineoplastic agents (221,099)
11/2013
11/13/2013CN102335234B Alkaloid extract of trembling poplar as well as extraction method and application thereof
11/13/2013CN102329810B siRNA conveying carrier and application thereof
11/13/2013CN102321133B Antibiotic Lobophorin E and F, preparation methods and applications thereof in preparing antibacterial and antitumor drugs
11/13/2013CN102268027B Amide Au (III) complex with antitumor activity
11/13/2013CN102266290B 4-(4-benzamido-phenoxyl)-2-(methyl-carbamyl) pyridine derivative or solid dispersion of salt derivative, as well as preparation method of derivative or solid dispersion
11/13/2013CN102260617B Royal jelly specially-produced wine and preparation technology thereof
11/13/2013CN102260297B Trehalose amide derivative as well as preparation method thereof and application thereof
11/13/2013CN102250109B Phenol compounds as well as preparation method and application thereof
11/13/2013CN102190663B Crystal form of Dimethylamino Arglabin hydrochloride
11/13/2013CN102174623B Fermentation method and application of yeast engineering bacteria
11/13/2013CN102133194B Preparation method and application of tanshinone II A solid dispersion pellets
11/13/2013CN102105448B Phenoxypyridinylamide derivatives and use thereof in the treatment of PDE4 mediated disease states
11/13/2013CN102093452B Hydrogenation type ginsenoside aglycons as well as preparation method and application of hydrogenation type ginsenoside aglycons
11/13/2013CN102083828B Heterocyclic compounds and compositions as C-KIT and PDGFR kinase inhibitors
11/13/2013CN102038640B Liposome medicament containing cholesterol PEG modifier and preparation method thereof
11/13/2013CN102015705B Fused heterocyclic derivative and use thereof
11/13/2013CN101932310B Method for preparing nanoparticles based on functional amphiphilic molecules or macromolecules, and the use thereof
11/13/2013CN101926780B Freeze-dried preparation of stabilized anthracycline compound
11/13/2013CN101921292B Novel siRNA chemical modification monomer, preparation method thereof and use thereof
11/13/2013CN101904848B Use of HIF alpha stabilizers for enhancing erythropoiesis
11/13/2013CN101883764B Pyrazole derivatives and use thereof as inhibitors of cyclin dependent kinases
11/13/2013CN101868464B Thienopyrimidiene derivatives as PI3k inhibitors
11/13/2013CN101786975B Lipoamide series derivates, preparation method and pharmaceutical application thereof
11/13/2013CN101687929B Monoclonal antibodies against claudin-18 for treatment of cancer
11/13/2013CN101605815B Method and arrangement for allowing enterprise and personal domains in the ims
11/13/2013CN101530573B Chinese medicine for treating tumor
11/13/2013CN101495501B Identification, optimization and use of cryptic HLA-B7 epitopes for immunotherapy
11/13/2013CN101472879B Novel crystal of 5-aminolevulinic acid phosphate and process for production thereof
11/13/2013CN101287764B Generation and profiling of fully human hucal gold-derived therapeutic antibodies specific for human cd38
11/12/2013US8580857 Methods and compositions to determine the chemosensitizing dose of suramin used in combination therapy
11/12/2013US8580806 Salts of 4-methyl N-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl-phenyl]-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-benzamide
11/12/2013US8580803 Substituted pyrrolo-aminopyrimidine compounds
11/12/2013US8580802 Pyrrolo[2,3-D]pyrimidines as inhibitors of Janus kinases
11/12/2013US8580783 [1,2,4]triazolo [1,5-c]pyrimidine derivatives as Hsp90 modulators
11/12/2013US8580782 Substituted pyrazolo[1,5-a]pyrimidines as cyclin dependent kinase inhibitors
11/12/2013US8580781 Pyridazinone derivatives
11/12/2013US8580761 Bispecific antisense oligonucleotides that inhibit IGFBP-2 and IGFBP-5 and methods of using same
11/12/2013US8580743 Modified galectin 9 proteins and methods of treatment using them
11/12/2013US8580544 Apparatus for introducing biological material, method of introducing biological material and magnetic support for introducing biological material
11/12/2013US8580312 Radiation therapy agent
11/12/2013US8580257 Antibodies that specifically block the biological activity of kidney associated antigen 1 (KAAG1)
11/12/2013US8580252 Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases
11/12/2013US8580244 Cyclodextrin-based polymers for therapeutics delivery
11/12/2013US8580243 Cyclodextrin-based polymers for therapeutics delivery
11/12/2013US8580242 Cyclodextrin-based polymers for therapeutics delivery
11/12/2013CA2623822C 1h-benzimidazole-4-carboxamides substituted with phenyl at the 2-position are potent parp inhibitors
11/12/2013CA2621836C Isoquinolines as igf-1r inhibitors
11/12/2013CA2615669C Salts of 4-methyl-n-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl-phenyl]-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-benzamide
11/12/2013CA2611474C Synergistic modulation of flt3 kinase using a flt3 inhibitor and a farnesyl transferase inhibitor
11/12/2013CA2549652C Cd40 antibody formulation and methods
11/12/2013CA2213451C Generation of human cytotoxic t-cells specific for carcinoma self-associated antigens and uses thereof
11/07/2013WO2013166470A2 Uses of cxcl17, a novel chemokine marker of human lung and gastrointestinal disease
11/07/2013WO2013166421A1 Melanoma chemoprevention
11/07/2013WO2013166366A1 Cul4b as predictive biomarker for cancer treatment
11/07/2013WO2013166321A1 Enhanced affinity t cell receptors and methods for making the same
11/07/2013WO2013166318A1 Combination therapy for treating bladder cancer
11/07/2013WO2013166296A1 A dual met - vegf modulator for treating osteolytic bone metastases
11/07/2013WO2013166206A1 A prenylated anthracenone polyketide as an immunosuppressant
11/07/2013WO2013166150A1 Compositions and methods for treating b-lymphoid malignancies
11/07/2013WO2013166110A1 Tlr-agonist-conjugated antibody recruiting molecules (tlr_arms)
11/07/2013WO2013166051A1 T cell receptor-deficient t cell compositions
11/07/2013WO2013166004A2 Organic compositions to treat kras-related diseases
11/07/2013WO2013165554A1 Methods and compositions for modulating g-alpha-q signaling
11/07/2013WO2013165320A1 Treating cancer by increasing expression of socs6
11/07/2013WO2013164593A1 Pyrrolobenzodiazepines
11/07/2013WO2013164473A1 Pharmaceutical composition comprising abiraterone acetate
11/07/2013WO2013164061A1 Pyrrolotriazinone derivatives
11/07/2013WO2013163893A1 Modified bacteria and uses thereof for treatment of cancer or tumor
11/07/2013WO2013163727A1 Protecting modified viruses from neutralizing antibodies using the reovirus sigma 1 protein
11/07/2013WO2013163724A1 Protecting modified viruses from neutralizing antibodies using the reovirus sigma 1 protein
11/07/2013WO2013095286A3 Synergistic combination comprising avermectins and a nsaid for tumor inhibition
11/07/2013WO2013009701A9 Metal bisphosphonate nanoparticles for anti-cancer therapy and imaging and for treating bone disorders
11/07/2013WO2002083860A9 Nucleic acid and corresponding protein entitled 151p3d4 useful in treatment and detection of cancer
11/07/2013US20130296411 Use of Artemisinin for Treating Tumors Induced by oncogenic Viruses and for Treating Viral Infections
11/07/2013US20130296404 Promoters Exhibiting Endothelial Cell Specificity and Methods of Using Same
11/07/2013US20130296359 Treatment of solid tumors with rapamycin derivatives
11/07/2013US20130295139 Adjuvant compositions and methods for enhancing immune responses to polynucleotide-based vaccines
11/07/2013US20130295128 Chimeric vaccines
11/07/2013US20130295078 Method of improving absorption of vitamin e by a pet animal
11/07/2013US20130295050 Anti-igf-i receptor antibodies, dnas, vectors, host cells and genetic constructs
11/07/2013US20130295009 Method of treating inflammation
11/06/2013EP2660241A2 C-17-heteroaryl steroidal compounds as inhibitors of cyp11b, cyp17, and/or cyp21
11/06/2013EP2660240A1 Benzopyrone estrogen receptor regulator
11/06/2013EP2659910A1 Method for suppressing receptor tyrosine kinase-mediated prosurvival signaling in cancer cells
11/06/2013EP2659902A1 Leuprolide injection
11/06/2013EP2659888A1 Use of aminolevulinic acid and derivatives thereof
11/06/2013EP2659884A2 Selective apoptotic induction in cancer cells including activation of procaspase-3
11/06/2013EP2658973A2 siRNA FOR INHIBITION OF Hif1alpha EXPRESSION AND ANTICANCER COMPOSITION CONTAINING THE SAME
11/06/2013EP2658873A2 A cross-linking polypeptide that induces apoptosis
11/06/2013EP2658872A1 A polypeptide that binds aberrant cells and induces apoptosis
11/06/2013EP2658871A1 Anti-cd38 antibodies
11/06/2013EP2658870A1 Conjugated anti-cd38 antibodies
11/06/2013EP2658869A1 Antigen binding formats for use in therapeutic treatments or diagnostic assays
11/06/2013EP2658852A2 Compositions and methods of using crystalline forms of wortmannin analogs
11/06/2013EP2658847A1 2 - (2 - phenylethenyl) - 1, 3 -benzothiazine derivatives useful for the treatment of cancer
11/06/2013EP2658844A1 Novel pyrimidine derivatives, preparation thereof, and pharmaceutical use thereof as akt(pkb) phosphorylation inhibitors
11/06/2013EP2658581A1 A conjugate of human albumin and 2-(4-isothiocyanatobenzyl)-1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid useful for the localization of radionuclides for diagnostic and therapeutic purposes
11/06/2013EP2658580A1 Arginase inhibitors and methods of use thereof
11/06/2013EP2658574A1 Polymalic acid-based nanobiopolymer compositions and methods for treating cancer
11/06/2013EP2658569A1 Combination of vaccination and inhibition of mhc class restricted antigen presentation
1 ... 117 118 119 120 121 122 123 124 125 126 127 128 129 130 131 132 133 134 135 136 137 ... 2211